SCHEMBL14256741

SCHEMBL14256741

CS(=O)(=O)N1CCC(Nc2nc(NCc3ccccc3Sc3ccccc3CO)nc3ccccc23)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WHR1 P49842 1/20 0.45
▸ EHMT2 Q96KQ7 2/20 0.43
▸ KDM1A O60341 1/20 0.43
▸ DNMT3A Q9Y6K1 1/20 0.42
▸ PDE5A O76074 3/20 0.41
▸ PTK2 Q05397 1/20 0.41
▸ APP P05067 2/20 0.41
▸ BCHE P06276 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ NPY5R Q15761 1/20 0.40
▸ OPRM1 P35372 1/20 0.40
▸ OPRD1 P41143 1/20 0.40
▸ OGFRL1 Q5TC84 1/20 0.40
▸ NSD2 O96028 2/20 0.40
▸ CCNT1 O60563 1/20 0.39
▸ CCND1 P24385 1/20 0.39
▸ CCNE1 P24864 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ CDK6 Q00534 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14412253 0.92 PDE5A (0.45) WHR1EHMT2KDM1ADNMT3APDE5A
SCHEMBL14256734 0.85 EHMT2 (0.47) WHR1EHMT2KDM1ADNMT3APDE5A
SCHEMBL14256444 0.85 MERTK (0.53) WHR1PDE5AAPPBCHEACHE
SCHEMBL14256699 0.84 MERTK (0.52) PDE5AAPPBCHEACHENPY5R
SCHEMBL14412273 0.82 EHMT2 (0.44) WHR1EHMT2KDM1ADNMT3AAPP
SCHEMBL14256736 0.82 DNMT3A (0.53) WHR1EHMT2KDM1ADNMT3AACHE
SCHEMBL14266659 0.82 EHMT2 (0.42) WHR1EHMT2KDM1ADNMT3APDE5A
SCHEMBL14412272 0.82 CXCR4 (0.52) WHR1APPBCHEACHEMERTK
SCHEMBL14256700 0.82 APP (0.46) WHR1EHMT2KDM1AAPPBCHE
SCHEMBL14256743 0.82 GBA1 (0.47) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058312-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2008-03-06 — — US disclosed
US-20080058312-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2008-03-06 — — US disclosed
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2007-09-13 — — US disclosed
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2007-09-13 — — US disclosed
WO-2007081978-A2 MODULATORS OF HEPATOCYTE GROWTH FACTOR / C-MET ACTIVITY ANGION BIOMEDICA CORPORATION (US) 2007-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity HGF, MET, HDGF WHR1 2846/4885EHMT2 1276/4885KDM1A 3012/4885
US-20080058312-A1 Modulators of hepatocyte growth factor/c-Met activity HGF, MET, HDGF WHR1 2803/4885EHMT2 1177/4885KDM1A 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback